Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review.
We report the case of a 76 year old man with three ulcerated basal cell carcinomas on his lower limbs. He was considered unsuitable for surgical therapy and was treated by intralesional interferon alpha-2b (Intron A) injections. Twenty months post therapy two of the three treatment sites remain clinically cured. Recurrence occurred at the site which received the smallest total dose of interferon. A review of the therapeutic trials of interferon alpha for basal cell carcinoma is presented. We conclude that interferon alpha-2b is a useful agent for treatment of basal cell carcinoma in selected patients.
McDonald
R R
RR
Lidcombe Hospital, NSW.
Georgouras
K
K
D000368:Aged; D002280:Basal Cell Carcinoma / Q000150:complications / Q000473:pathology / Q000628:therapy*; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007866:Leg; D007871:Leg Ulcer / Q000150:complications; D008297:Male; D009364:Neoplasm Recurrence, Local; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins